Skip to main content
Case Report

Potential Synergy of Lithium and Ketamine in Treatment of Recurrent Major Depression

    Psychiatric Annals, 2022;52(4):170–172
    Published Online:https://doi.org/10.3928/00485713-20220302-01

    Abstract

    Combination pharmacotherapy has proven to be effective in the treatment of major depressive disorder (MDD), particularly when medications from different drug classes are combined. Lithium and ketamine, although typically not prescribed as first-line treatments, have been used individually to augment the effects of antidepressants; however, little is known about the efficacy of combined lithium and ketamine therapy in treating MDD. We present a patient diagnosed as having MDD whose biweekly ketamine infusions augmented with lithium resulted in an improvement of depressive symptoms, leading to a successful discharge following 2.5 months of hospitalization, during which the patient failed to show improvement with both electroconvulsive therapy and trials of multiple classes of antidepressants. [Psychiatr Ann. 2022;52(4):170–172.]

    • 1.Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013; 346:f3646. 10.1136/bmj.f3646 PMID:23814104

      > CrossrefGoogle Scholar
    • 2.Erden A, Karagöz H, Başak Met al.. Lithium intoxication and nephrogenic diabetes insipidus: a case report and review of literature. Int J Gen Med. 2013; 6:535–539. 10.2147/IJGM.S46383 PMID:23861592

      > CrossrefGoogle Scholar
    • 3.Bratsos S, Saleh SN. Clinical efficacy of ketamine for treatment-resistant depression. Cureus. 2019; 11(7):e5189. 10.7759/cureus.5189 PMID:31565597

      > CrossrefGoogle Scholar
    • 4.Shin C, Kim YK. Ketamine in major depressive disorder: mechanisms and future perspectives. Psychiatry Investig. 2020; 17(3):181–192. 10.30773/pi.2019.0236 PMID:32209965

      > CrossrefGoogle Scholar
    • 5.Corriger A, Pickering G. Ketamine and depression: a narrative review. Drug Des Devel Ther. 2019; 13:3051–3067. 10.2147/DDDT.S221437 PMID:31695324

      > CrossrefGoogle Scholar
    • 6.Santarsieri D, Schwartz TL. Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs Context. 2015; 4:212290. 10.7573/dic.212290 PMID:26576188

      > CrossrefGoogle Scholar
    • 7.Su TP, Chen MH, Li CTet al.. Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology. 2017; 42(13:2482–2492. 10.1038/npp.2017.94 Erratum in: Neuropsychopharmacology. 2019;44(3):655–656. PMID: 28492279

      > CrossrefGoogle Scholar
    • 8.Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010; 167(3):281–288. 10.1176/appi.ajp.2009.09020186 PMID:20008946

      > CrossrefGoogle Scholar
    • 9.Chiu CT, Scheuing L, Liu Get al.. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. Int J Neuropsychopharmacol. 2014; 18(6):pyu102. 10.1093/ijnp/pyu102 PMID: 25548109

      > CrossrefGoogle Scholar
    • 10.Liu RJ, Fuchikami M, Dwyer JM, Lepack AE, Duman RS, Aghajanian GK. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology. 2013; 38(11):2268–2277. 10.1038/npp.2013.128 PMID:23680942

      > CrossrefGoogle Scholar
    • 11.Ghasemi M, Raza M, Dehpour AR. NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test. J Psychopharmacol. 2010; 24(4):585–594. 10.1177/0269881109104845 PMID: 19351802.

      > CrossrefGoogle Scholar
    • 12.Diazgranados N, Ibrahim L, Brutsche NEet al.. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010; 67(8):793–802. 10.1001/archgenpsychiatry.2010.90 PMID:20679587

      > CrossrefGoogle Scholar
    • 13.Zarate CA, Brutsche NE, Ibrahim Let al.. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 20121; 71(11):939–946. 10.1016/j.biopsych.2011.12.010 PMID:22297150

      > CrossrefGoogle Scholar
    • 14.Rybakowski JK, Permoda-Osip A, Bartkowska-Sniatkowska A. Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression. Int J Psychiatry Clin Pract. 2017; 21(2):99–103. 10.1080/13651501.2017.1297834 PMID:28271731

      > CrossrefGoogle Scholar
    • 15.Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Zarate CA. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord. 2015; 17(4):438–443. 10.1111/bdi.12277 PMID:25400146

      > CrossrefGoogle Scholar

    We use cookies on this site to enhance your user experience. For a complete overview of all the cookies used, please see our privacy policy.

    ×